Thermo Fisher Scientific (TMO) total liabilities
Thermo Fisher Scientific (TMO) had total liabilities of $56.81B at the end of fiscal 2025 (December 31, 2025). That is 19.2% higher than the $47.65B of fiscal 2024. Figures as of 18 Nov 2026, 20:50 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $56.81B
- Change on fiscal 2024
- +19.2%
- Highest on record
- $56.81Bfiscal 2025
- Lowest on record
- $47.65Bfiscal 2024
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Thermo Fisher Scientific total liabilities, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $56.81B in fiscal 2025 and the lowest $47.65B in fiscal 2024.
Total liabilities by fiscal year
Thermo Fisher Scientific total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $56.81B | 19.2% up | |
| 2024 | $47.65B | 8.2% down | |
| 2023 | $51.88B | 2.1% down | |
| 2022 | $53.01B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| UnitedHealth Group UNH | $207.88B | 2025 |
| Novartis NVS | $64.40B | 2025 |
| AstraZeneca AZN | $65.36B | 2025 |
| Thermo Fisher Scientific TMO | $56.81B | 2025 |
| Amgen AMGN | $81.93B | 2025 |
| Gilead Sciences GILD | $36.41B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Thermo Fisher Scientific, figure by figure
- Thermo Fisher Scientific market cap
- Thermo Fisher Scientific revenue
- Thermo Fisher Scientific earnings
- Thermo Fisher Scientific earnings per share (EPS)
- Thermo Fisher Scientific P/E ratio
- Thermo Fisher Scientific P/S ratio
- Thermo Fisher Scientific P/B ratio
- Thermo Fisher Scientific free cash flow
- Thermo Fisher Scientific operating margin
- Thermo Fisher Scientific dividend
- Thermo Fisher Scientific shares outstanding
- Thermo Fisher Scientific total debt
- Thermo Fisher Scientific cash on hand
- Thermo Fisher Scientific total assets
- Thermo Fisher Scientific net assets (shareholders' equity)
- Thermo Fisher Scientific return on equity (ROE)
- Thermo Fisher Scientific return on invested capital (ROIC)
Thermo Fisher Scientific (TMO) overview: price, valuation and scorecardAll health care companies by market value
Thermo Fisher Scientific total liabilities: questions and answers
How large are Thermo Fisher Scientific's total liabilities?
Thermo Fisher Scientific (TMO) had total liabilities of $56.81B at the end of fiscal 2025 (December 31, 2025). That is 19.2% higher than the $47.65B of fiscal 2024.
What are the highest and lowest total liabilities figures on record for Thermo Fisher Scientific?
Across the 4 fiscal years on record (2022–2025), the highest was $56.81B in fiscal 2025 and the lowest $47.65B in fiscal 2024.
How is Thermo Fisher Scientific's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Thermo Fisher Scientific it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Thermo Fisher Scientific (TMO) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/TMO/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.